Journal of Infectious Diseases and Diagnosis

In silico Discovery Research Academic Services Private Limited Hyderabad, Telangana 500040, India

Biography

Dr. Sreedhara Voleti is the Founder, Managing Director of INDRAS Pvt. Ltd. He is a passionate entrepreneur, consultant, start-up entertainer, leader, and mentor with over 20 years of pharma R & D experience. He was Co-Founder and CSO at Theraxel Discoveries Pvt. Ltd and Head of CADD at Ranbaxy and ILS. He obtained his Ph.D. from IISc Bangalore and Post-Docs from University of Massachusetts and Washington State University, USA.

Publications

• Mini Review   
  Emergence of New Drug Discovery Paradigm using Computational and Experimental Biology: Case Study of using Repurposing Drugs for COVID-19
  Author(s): Sreedhara Voleti*, Shalini Saxena and Uday Saxena
  
  Discovery of new drugs is an expensive and time-consuming process. Average time taken from bench to bedside (idea to drug launch) is about 12 years including clinical trials. The emergence of COVID-19 pandemic has demonstrated that there is a dire need to be able to launch therapeutics much sooner than the traditional timelines. As such the industry is reinventing the process to deliver drugs much faster. As such we present here a new paradigm of identifying drugs for COVID-19. It uses three fundamental principles, viz., 1) using existing FDA approved drugs which have been approved for other diseases, so their safety is proven, 2) Using computational rational approaches for choosing the best drugs against the target of interest such as the Receptor Binding Domain of the Spike Protein of COVID-19, and, finally, 3) validation of these short-listed drugs through in vitro .. View more»
  

  DOI: 10.37421/2576-389X.2021.6.152

  Abstract HTML PDF